Walden Biosciences
Biotechnology company relentlessly focused on developing first-in-class, highly-targeted therapies for individuals living with kidney disease.
| Date | Investors | Amount | Round |
|---|---|---|---|
| - | investor | €0.0 | round |
| investor investor | €0.0 | round | |
N/A | Series B | ||
| Total Funding | 000k | ||
Related Content
Walden Biosciences is a biotech startup that operates in the healthcare sector, specifically focusing on the treatment of kidney diseases. The company's mission is to transform the treatment landscape of chronic kidney disease (CKD) and acute kidney injury (AKI). CKD is a condition where the kidneys are progressively damaged and fail over time, while AKI is a rapid loss of kidney function in a short period.
The company's target market is vast, with over 850 million people worldwide suffering from some form of kidney disease. In the US alone, there are 37 million patients with CKD. This number is significantly higher than the number of people suffering from cancer, HIV/AIDS, or diabetes.
Walden Biosciences' business model revolves around the development and commercialization of innovative treatments for kidney diseases. The company generates revenue by conducting clinical trials and eventually selling the developed drugs. Recently, they announced the first subject dosed in their first-in-humans Phase 1 Clinical Trial of WAL0921, a drug in development for the treatment of chronic kidney diseases.
The company also hosts virtual events to educate and engage with the public and potential investors about their work and the importance of their mission. The next event, titled "Transforming the Treatment Landscape of Chronic Kidney Disease," is scheduled for November 14, 2023.
Keywords: Biotech, Healthcare, Kidney Disease, Chronic Kidney Disease (CKD), Acute Kidney Injury (AKI), Clinical Trials, Drug Development, Virtual Events, Patient Engagement, Innovative Treatments.